Biomarin Pharmaceutical Inc logo

Biomarin Pharmaceutical Inc

MXN 2082.00 (+0.05%) Feb 8
P/E:
259.03
P/B:
4.43
Market Cap:
MXN 387.71B ($ 20.49B)
Enterprise V:
MXN 384.26B ($ 20.30B)
Volume:
5.00
Avg Vol (2M):
978.00
Also Trade In:
Volume:
5.00
Market Cap MXN:
387.71B
Market Cap $:
20.49B
PE Ratio:
259.03
Avg Vol (2-Month):
978.00
Enterprise Value MXN:
384.26B
Enterprise Value $:
20.30B
PB Ratio:
4.43

Business Description

Description
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe.
Name Current Vs Industry Vs History
Cash-To-Debt 1.17
Equity-to-Asset 0.73
Debt-to-Equity 0.24
Debt-to-EBITDA 4.97
Interest Coverage 0.23
Piotroski F-Score 8/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 7.94
Distress
Grey
Safe
Beneish M-Score -2.55
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 62.79
9-Day RSI 53.57
14-Day RSI 61.34
6-1 Month Momentum % 8.5
12-1 Month Momentum % 21.88

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.15
Quick Ratio 3.54
Cash Ratio 2.44
Days Inventory 606.26
Days Sales Outstanding 75.05
Days Payable 151.87

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -1

Financials (Next Earnings Date:2023-02-23 Est.)

MEX:BMRN's 30-Y Financials

How Biomarin Pharmaceutical Inc (MEX:BMRN) Makes Its Money

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
To

Annualized Return %

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %

Symbol
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014

Executives

Details

Valuation chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil MXN) 40,905.693
EPS (TTM) (MXN) 8.446
Beta 0
Volatility % 26.87
14-Day RSI 61.34
14-Day ATR (MXN) 2.640535
20-Day SMA (MXN) 2077.47
12-1 Month Momentum % 21.88
52-Week Range (MXN) 1490 - 2132.23
Shares Outstanding (Mil) 185.85

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 8
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Biomarin Pharmaceutical Inc Filings

Document Form Filing Date
No Filing Data

Biomarin Pharmaceutical Inc Stock Events

Event Date Price(MXN)
No Event Data

Press Release

Subject Date
No Press Release